134 related articles for article (PubMed ID: 11919162)
1. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin.
Chekenya M; Hjelstuen M; Enger PØ; Thorsen F; Jacob AL; Probst B; Haraldseth O; Pilkington G; Butt A; Levine JM; Bjerkvig R
FASEB J; 2002 Apr; 16(6):586-8. PubMed ID: 11919162
[TBL] [Abstract][Full Text] [Related]
2. The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours.
Chekenya M; Enger PØ; Thorsen F; Tysnes BB; Al-Sarraj S; Read TA; Furmanek T; Mahesparan R; Levine JM; Butt AM; Pilkington GJ; Bjerkvig R
Neuropathol Appl Neurobiol; 2002 Oct; 28(5):367-80. PubMed ID: 12366818
[TBL] [Abstract][Full Text] [Related]
3. Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen).
Goretzki L; Lombardo CR; Stallcup WB
J Biol Chem; 2000 Sep; 275(37):28625-33. PubMed ID: 10889192
[TBL] [Abstract][Full Text] [Related]
4. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA.
Tanaka T; Cao Y; Folkman J; Fine HA
Cancer Res; 1998 Aug; 58(15):3362-9. PubMed ID: 9699667
[TBL] [Abstract][Full Text] [Related]
5. Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.
Wang J; Svendsen A; Kmiecik J; Immervoll H; Skaftnesmo KO; Planagumà J; Reed RK; Bjerkvig R; Miletic H; Enger PØ; Rygh CB; Chekenya M
PLoS One; 2011; 6(7):e23062. PubMed ID: 21829586
[TBL] [Abstract][Full Text] [Related]
6. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression.
Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
Cancer Gene Ther; 2001 Oct; 8(10):719-27. PubMed ID: 11687895
[TBL] [Abstract][Full Text] [Related]
7. NG2 Proteoglycan-Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression.
Stallcup WB; You WK; Kucharova K; Cejudo-Martin P; Yotsumoto F
Microcirculation; 2016 Feb; 23(2):122-33. PubMed ID: 26465118
[TBL] [Abstract][Full Text] [Related]
8. Angiostatin suppresses malignant glioma growth in vivo.
Kirsch M; Strasser J; Allende R; Bello L; Zhang J; Black PM
Cancer Res; 1998 Oct; 58(20):4654-9. PubMed ID: 9788618
[TBL] [Abstract][Full Text] [Related]
9. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization.
Pozzi A; Moberg PE; Miles LA; Wagner S; Soloway P; Gardner HA
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2202-7. PubMed ID: 10681423
[TBL] [Abstract][Full Text] [Related]
10. NG2 expression regulates vascular morphology and function in human brain tumours.
Brekke C; Lundervold A; Enger PØ; Brekken C; Stålsett E; Pedersen TB; Haraldseth O; Krüger PG; Bjerkvig R; Chekenya M
Neuroimage; 2006 Feb; 29(3):965-76. PubMed ID: 16253523
[TBL] [Abstract][Full Text] [Related]
11. NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours.
Chekenya M; Pilkington GJ
J Neurocytol; 2002; 31(6-7):507-21. PubMed ID: 14501220
[TBL] [Abstract][Full Text] [Related]
12. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer.
Sim BK; O'Reilly MS; Liang H; Fortier AH; He W; Madsen JW; Lapcevich R; Nacy CA
Cancer Res; 1997 Apr; 57(7):1329-34. PubMed ID: 9102221
[TBL] [Abstract][Full Text] [Related]
13. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.
Yokoyama Y; Dhanabal M; Griffioen AW; Sukhatme VP; Ramakrishnan S
Cancer Res; 2000 Apr; 60(8):2190-6. PubMed ID: 10786683
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin.
De Boüard S; Guillamo JS; Christov C; Lefévre N; Brugières P; Gola E; Devanz P; Indraccolo S; Peschanski M
Hum Gene Ther; 2003 Jun; 14(9):883-95. PubMed ID: 12828859
[TBL] [Abstract][Full Text] [Related]
15. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.
Cao Y; O'Reilly MS; Marshall B; Flynn E; Ji RW; Folkman J
J Clin Invest; 1998 Mar; 101(5):1055-63. PubMed ID: 9486976
[TBL] [Abstract][Full Text] [Related]
16. NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function.
You WK; Yotsumoto F; Sakimura K; Adams RH; Stallcup WB
Angiogenesis; 2014 Jan; 17(1):61-76. PubMed ID: 23925489
[TBL] [Abstract][Full Text] [Related]
17. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
[TBL] [Abstract][Full Text] [Related]
18. NG2 proteoglycan-binding peptides target tumor neovasculature.
Burg MA; Pasqualini R; Arap W; Ruoslahti E; Stallcup WB
Cancer Res; 1999 Jun; 59(12):2869-74. PubMed ID: 10383148
[TBL] [Abstract][Full Text] [Related]
19. Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2.
Moses MA; O'Reilly MS
Methods Mol Med; 2003; 74():375-90. PubMed ID: 12415709
[No Abstract] [Full Text] [Related]
20. Expression of the chondroitin sulphate proteoglycan, NG2, in paediatric brain tumors.
Higgins SC; Bolteus AJ; Donovan LK; Hasegawa H; Doey L; Al Sarraj S; King A; Ashkan K; Roncaroli F; Fillmore HL; Pilkington GJ
Anticancer Res; 2014 Dec; 34(12):6919-24. PubMed ID: 25503117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
